Literature DB >> 18388013

Diagnosis and management of venous ulcers.

Sandra C Carr1.   

Abstract

Venous ulceration of the lower extremities is a common and often disabling condition. Venous ulcers are the result of a chronic inflammatory condition caused by persistent venous hypertension. Therapy is directed at counteracting the chronic inflammation in the tissues and at decreasing ambulatory venous hypertension in the area. Compression therapy helps decrease the venous hypertension and aids healing. Topical agents may be used to help decrease the bacterial load in the wound, provide a moist healing environment for dry wounds, or absorb the exudate in wounds with a lot of drainage. Pharmacological adjuncts, such as pentoxifylline or flavanoids, may help counteract the chronic inflammation in the ulcerated area. Interventions to decrease the ambulatory venous hypertension can help patients with either active or healed ulcers. Ablation of incompetent superficial truncal veins and/or perforating veins using radiofrequency ablation, endovenous laser ablation, or foam sclerotherapy can speed ulcer healing and prevent recurrence.

Entities:  

Mesh:

Year:  2008        PMID: 18388013     DOI: 10.1177/1531003507313218

Source DB:  PubMed          Journal:  Perspect Vasc Surg Endovasc Ther        ISSN: 1521-5768


  3 in total

1.  Endovenous ablation for the treatment of chronic venous insufficiency and venous ulcerations.

Authors:  Christopher J Marrocco; Marvin D Atkins; W Todd Bohannon; Thomas R Warren; Clifford J Buckley; Ruth L Bush
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

2.  The impact of skin grafting on the quality of life and self-esteem of patients with venous leg ulcers.

Authors:  Geraldo M Salomé; Leila Blanes; Lydia M Ferreira
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

3.  Impact of skin grafting of venous leg ulcers on functional status and pain.

Authors:  Geraldo Magela Salomé; Lydia M Ferreira
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.